Kenneth Adams
Cardiovascular Disease · Jacksonville, FLNPI 1881696284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $684 and has fallen 96.6% since, to $24 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 141 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$460
- Johnson & Johnson$207
- Merck$200
- Novartis$197
- E.r. Squibb & Sons, L.L.C.$194
- Abbott$166
- plus $1K from 17 others
Across 1 payment — averaging $16,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$16K
What the payments were for
- Food & beverage$2,40097%
- Education$763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $460 |
| Johnson & Johnson | 14 | $207 |
| Merck | 12 | $200 |
| Novartis | 13 | $197 |
| E.r. Squibb & Sons, L.L.C. | 14 | $194 |
| Abbott | 3 | $166 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $134 |
| Pfizer | 7 | $130 |
| Scpharmaceuticals Inc. | 1 | $124 |
| Astellas Pharma US Inc | 5 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Amarin Pharma, Inc. | 5 | $85 |
| AstraZeneca | 5 | $80 |
| Biotronik Inc. | 1 | $76 |
| Boehringer Ingelheim | 4 | $65 |
| AbbVie | 2 | $46 |
| Boston Scientific | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Gilead | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$130
- FUROSCIX$124
- Repatha$109
How this compares
$2,476 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.